Literature DB >> 8923828

Apparent cortisone reductase deficiency: a unique form of hypercortisolism.

G Phillipov1, M Palermo, C H Shackleton.   

Abstract

We describe two female siblings who had production of cortisol (F; as determined from excretion of urinary metabolites) high enough to give rise to Cushing's disease, but who had no clinical indications of the condition. The teenage patients were hirsute as a result of adrenal hyperandrogenism. A notable feature of the condition was the elevated excretion of corticosteroid metabolites with 11-carbonyl groups and very low excretion of 11 beta-hydroxylated steroids. We termed this disorder apparent cortisone (E) reductase disorder. The steroid metabolite phenotype appeared to be the opposite of that seen in the apparent mineralocorticoid excess syndrome, in which the excretion of 11-keto compounds is attenuated. As an example, the tetrahydrocortisol plus 5 alpha-tetrahydrocortisol/tetrahydrocortisone ratio was about 0.04 compared to normal values of about 1.0 and apparent mineralocorticoid excess syndrome values of 5.0-50.0. Paradoxically, among the F metabolites that had not undergone A-ring reduction, 11 beta-hydroxylated steroids dominated over 11-carbonyl compounds. The F/E ratio was about 1.8 compared to an average normal value of 0.54. Neither the father nor the mother of the patient had abnormal F metabolite/E metabolite ratios, although the father did excrete highly elevated free E and F, possibly an unrelated condition. A conclusion was not reached regarding the basis of the disorder. We considered that the most likely causes were 1) defective hepatic 11 beta-hydroxysteroid dehydrogenase-1, 2) failure to develop the adult form of F metabolism, or 3) excessive activity of A ring reduction enzymes acting on E.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923828     DOI: 10.1210/jcem.81.11.8923828

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

Review 3.  Role of a disordered steroid metabolome in the elucidation of sterol and steroid biosynthesis.

Authors:  Cedric H L Shackleton
Journal:  Lipids       Date:  2011-08-27       Impact factor: 1.880

Review 4.  Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism.

Authors:  Perrin C White; Daniela Rogoff; D Randy McMillan; Gareth G Lavery
Journal:  Mol Cell Endocrinol       Date:  2007-01-19       Impact factor: 4.102

5.  Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis.

Authors:  Elvy Suhana Mohd Ramli; Farihah Suhaimi; Siti Fadziyah Mohamad Asri; Fairus Ahmad; Ima Nirwana Soelaiman
Journal:  J Bone Miner Metab       Date:  2012-12-30       Impact factor: 2.626

Review 6.  Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS).

Authors:  Nils Krone; Beverly A Hughes; Gareth G Lavery; Paul M Stewart; Wiebke Arlt; Cedric H L Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-22       Impact factor: 4.292

7.  Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Alexander J Lawson; Elizabeth A Walker; Gareth G Lavery; Iwona J Bujalska; Beverly Hughes; Wiebke Arlt; Paul M Stewart; Jonathan P Ride
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

8.  Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.

Authors:  Gareth G Lavery; Elizabeth A Walker; Ana Tiganescu; Jon P Ride; Cedric H L Shackleton; Jeremy W Tomlinson; John M C Connell; David W Ray; Anna Biason-Lauber; Ewa M Malunowicz; Wiebke Arlt; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

9.  Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling.

Authors:  G G Lavery; J Idkowiak; M Sherlock; I Bujalska; J P Ride; K Saqib; M F Hartmann; B Hughes; S A Wudy; J De Schepper; W Arlt; N Krone; C H Shackleton; E A Walker; P M Stewart
Journal:  Eur J Endocrinol       Date:  2013-02-01       Impact factor: 6.664

10.  Relative adrenal insufficiency in mice deficient in 5α-reductase 1.

Authors:  Dawn E W Livingstone; Emma M Di Rollo; Chenjing Yang; Lucy E Codrington; John A Mathews; Madina Kara; Katherine A Hughes; Christopher J Kenyon; Brian R Walker; Ruth Andrew
Journal:  J Endocrinol       Date:  2014-05-28       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.